scholarly journals Prognostic Nomograms for Predicting Overall Survival and Cancer-Specific Survival of Patients with Major Salivary Gland Mucoepidermoid Carcinoma

2019 ◽  
Vol 10 (18) ◽  
pp. 4380-4388 ◽  
Author(s):  
Jia-Qian Hu ◽  
Peng-Cheng Yu ◽  
Xiao Shi ◽  
Wan-Lin Liu ◽  
Ting-Ting Zhang ◽  
...  
Keyword(s):  
Overall Survival ◽  
Salivary Gland ◽  
Mucoepidermoid Carcinoma ◽  
Major Salivary Gland ◽  
Cancer Specific Survival

Complications of radio- and radiochemotherapy in patients undergoing major salivary gland cancer surgery

2019 ◽  
Vol 73 (3) ◽  
pp. 26-31
Author(s):  
Izabela Kordzińska-Cisek ◽  
Ludmiła Grzybowska-Szatkowska
Keyword(s):  
Overall Survival ◽  
Salivary Gland ◽  
Subcutaneous Tissue ◽  
Tnm Classification ◽  
Healing Time ◽  
Salivary Gland Cancer ◽  
Major Salivary Gland ◽  
Radiation Induced ◽  
Early Radiation ◽  
Induced Reaction

Purpose: The aim of this retrospective study was to present the prevalence of early and late radiation-induced reaction and factors affecting its formation and severity in patients after adjuvant radio- or radiochemotherapy in salivary gland cancer. Material and methods: A total of 113 patients with early and 91 with late radiation-induced reaction, irradiated in 2006-2016 were enrolled in the study. The frequency of acute mucosal radiation-induced reaction, time of onset, intensity, healing time, as well as the incidence of late radiation-induced reaction from the skin and subcutaneous tissue were analyzed. Factors that could influence the development and intensity of reaction were identified. Results: Acute severity and the presence of late radiation-induced reaction do not affect overall survival. Dosage in the tumor bed site, as well as the dosage in the nodal region, affect the severity of the acute radiation-induced mucosal reaction. The severity of the early radiation-induced reaction is higher in men, more advanced patients (higher T and N+ in TNM classification), irradiated into a larger area, and those in whom two-dimensional planning and complementary chemoradiotherapy were applied. The late reaction of the skin and subcutaneous tissue was dominated by patients irradiated in the nodal regions and those with a higher intensity of early radiation-induced reaction. Conclusions: Supplementary radiotherapy or radiochemotherapy in salivary gland cancer is associated with acceptable toxicity which has no effect on overall survival.

scholarly journals A clinical study of the incidence of salivary gland tumors in a tertiary care teaching hospital

2019 ◽  
Vol 6 (6) ◽  
pp. 2110
Author(s):  
Sathish Babu N. ◽  
Naveen H. Mahadev ◽  
Kumar G. V.
Keyword(s):  
Salivary Gland ◽  
Pleomorphic Adenoma ◽  
Mucoepidermoid Carcinoma ◽  
Critical Role ◽  
Tertiary Care ◽  
Malignant Neoplasm ◽  
Salivary Gland Tumour ◽  
Major Salivary Gland ◽  
Salivary Gland Tumours ◽  
Gland Tumour

Background: The salivary gland system of the upper aero digestive tract plays a critical role in the functions of digestion, respiration, communication, and overall homeostasis. The Salivary gland swellings can be broadly classified into inflammatory, non-inflammatory and neoplastic swellings like calculi, benign tumours such has pleomorphic adenoma, oncocytoma, Warthin's tumour, malignant tumors which include-adenocarcinoma, adenoid cystic carcinoma, undifferentiated carcinoma.Methods: The present cross-sectional study was conducted at the Department of general surgery, Sri Siddhartha Medical College over a period of 2 years from August 2016 to July 2018.  All major salivary gland neoplastic swellings confirmed by FNAC were included in this study.Results: In our study 23 patients had major salivary gland tumours out of that 19 patients had parotid and 4 had submandibular major salivary gland tumour. In our study out 23 cases of salivary tumours 19 cases were benign and 4 cases were malignant, out of 19 cases of parotid tumours, 15 (78.94%) cases were seen in superficial lobe and 4 (21.06%) were in deep lobe, out of 23 salivary gland tumours, 19 (82.6%) cases were pleomorphic adenoma 3(13.05%) cases were mucoepidermoid carcinoma and one case (4.35%) was acinic cell carcinoma.Conclusions: Parotid gland was the most common site of origin of both benign and malignant tumours, Pleomorphic adenoma was the most common benign salivary gland tumour and mucoepidermoid carcinoma was the most frequent malignant neoplasm.

Prediction of Minor Salivary Gland Carcinoma: A Novel Nomogram and Risk Classification System for Overall Survival and Cancer-Specific Survival

2020 ◽  
pp. 019459982093832
Author(s):  
Ling-feng lan ◽  
Chen-kai Gao ◽  
Chao-wu Ma
Keyword(s):  
Overall Survival ◽  
Salivary Gland ◽  
Minor Salivary Gland ◽  
Proportional Hazard ◽  
Seer Database ◽  
Concordance Index ◽  
Salivary Gland Carcinoma ◽  
Cancer Specific Survival ◽  
Cox Proportional Hazard ◽  
Gland Carcinoma

Objective Minor salivary gland carcinoma (MiSGC) is rare, and the understanding of this disease is insufficient. This study aimed to identify independent risk factors and develop a nomogram for evaluating the overall survival (OS) and cancer-specific survival (CSS) of patients with MiSGC. Study Design Retrospective cohort study. Setting SEER database (Surveillance, Epidemiology, and End Results). Subjects and Methods We collected data from patients diagnosed with MiSGC between 2004 and 2015 from the SEER database. According to patient registration, all patients were randomly allocated to training sets and validation sets (2:1). Then, Kaplan-Meier product limit curves and Cox proportional hazard regressions were performed to estimate the prognostic effect of variables. Nomograms based on Cox proportional hazard regressions were established to estimate 3- and 5-year OS and CSS. Finally, the nomogram was developed by the training set, and validation was performed with the concordance index, calibration curves, and decision curve analyses. Results In total, 1787 MiSGC cases were registered in SEER. The concordance index for internal validation of OS and CSS prediction was 0.842 and 0.816; that of external validation was 0.871 and 0.831. The calibration plots showed good consistency between nomogram prediction and actual survival. The decision curve analysis showed substantial net benefits of the new predictive model. Conclusions We constructed nomograms and a corresponding risk classification system predicting the OS and CSS of patients with MiSGC. These tools can generate simple-to-use clinical risk grouping and determine the relationship between adjuvant therapy and active surveillance.

Oncocytic differentiation in salivary gland tumours

1995 ◽  
Vol 109 (6) ◽  
pp. 569-571 ◽  
Author(s):  
Jorge A. Ferreiro ◽  
Nickolaos Stylopoulos
Keyword(s):  
Salivary Gland ◽  
Parotid Gland ◽  
Facial Nerve ◽  
Mucoepidermoid Carcinoma ◽  
Facial Nerve Paralysis ◽  
Major Salivary Gland ◽  
Superficial Parotidectomy ◽  
Nerve Paralysis ◽  
Salivary Gland Tumours ◽  
Pleomorphic Adenomas

AbstractAn oncocytic mucoepidermoid carcinoma and an oncocytic pleomorphic adenoma occurred in a 47-year-old male and a 75-year-old female, respectively. Both presented as asymptomatic parotid gland masses without evidence of facial nerve paralysis and were treated by superficial parotidectomy. There has been no evidence of recurrence or metastasis. Oncocytic change is rare in major salivary gland mucoepidermoid carcinoma with only two previously reported cases. Marked oncocytic transformation of pleomorphic adenomas can cause their confusion with oncocytomas. Recognition of oncocytic differentiation in various salivary gland tumours is important to avoid misclassification of these lesions.

scholarly journals Proton Therapy for Major Salivary Gland Cancer: Clinical Outcomes

2021 ◽  
Vol 8 (1) ◽  
pp. 261-272
Author(s):  
Alexander N. Hanania ◽  
Xiaodong Zhang ◽  
G. Brandon Gunn ◽  
David I. Rosenthal ◽  
Adam S. Garden ◽  
...  
Keyword(s):  
Overall Survival ◽  
Salivary Gland ◽  
Proton Beam ◽  
Local Control ◽  
Proton Therapy ◽  
Late Toxicity ◽  
Proton Beam Therapy ◽  
Major Salivary Gland ◽  
Grade 3

Abstract Purpose To report clinical outcomes in terms of disease control and toxicity in patients with major salivary gland cancers (SGCs) treated with proton beam therapy. Materials and Methods Clinical and dosimetric characteristics of patients with SGCs treated from August 2011 to February 2020 on an observational, prospective, single-institution protocol were abstracted. Local control and overall survival were calculated by the Kaplan-Meier method. During radiation, weekly assessments of toxicity were obtained, and for patients with ≥ 90 days of follow-up, late toxicity was assessed. Results Seventy-two patients were identified. Median age was 54 years (range, 23-87 years). Sixty-three patients (88%) received postoperative therapy, and nine patients (12%) were treated definitively. Twenty-six patients (36%) received concurrent chemotherapy. Nine patients (12%) had received prior radiation. All (99%) but one patient received unilateral treatment with a median dose of 64 GyRBE (relative biological effectiveness) (interquartile range [IQR], 60-66), and 53 patients (74%) received intensity-modulated proton therapy with either single-field or multifield optimization. The median follow-up time was 30 months. Two-year local control and overall survival rates were 96% (95% confidence interval [CI] 85%-99%) and 89% (95% CI 76%-95%], respectively. Radiation dermatitis was the predominant grade-3 toxicity (seen in 21% [n = 15] of the patients), and grade ≥ 2 mucositis was rare (14%; n = 10 patients). No late-grade ≥ 3 toxicities were reported. Conclusion Proton beam therapy for treatment of major SGCs manifests in low rates of acute mucosal toxicity. In addition, the current data suggest a high rate of local control and minimal late toxicity.

scholarly journals Pattern of Major Salivary Gland Malignancy in B.P. Koirala Memorial Cancer Hospital

2019 ◽  
Vol 15 (3) ◽  
pp. 202-205
Author(s):  
Rajina Sahi ◽  
Dilip Karmacharya ◽  
Dej Kumar Gautam ◽  
Anil Bikram Karki ◽  
Amar Shrestha
Keyword(s):  
Salivary Gland ◽  
Parotid Gland ◽  
Malignant Tumor ◽  
Mucoepidermoid Carcinoma ◽  
Salivary Gland Tumor ◽  
Major Salivary Gland ◽  
Gland Tumor ◽  
Malignant Salivary Gland Tumor ◽  
Cancer Hospital ◽  
Salivary Gland Malignancy

Background: Salivary gland tumors represent a different variety of histological types. The definite diagnosis of type of salivary gland tumor is required for proper treatment planning. The aim of this study was to evaluate the pattern of salivary gland malignancy in B.P. Koirala Memorial Cancer Hospital, Bharatpur, Chitwan. Methods: This cross-sectional study was carried out in patients of malignant salivary gland tumor registered in B.P. Koirala Memorial Cancer hospital retrospectively from September 2009 to August 2012. Results: Parotid gland was the most common sites for malignant salivary gland tumor (80%) followed by submandibular gland (20%). Mucoepidermoid carcinoma is the most common malignant salivary gland tumor of parotid gland and Adenoid cystic carcinoma was the most common malignant tumor of submandibu-lar gland. Male: Female ratio was 1.5:1 with age range from 12 years to 71 years. Common age group for malignant salivary gland tumor was from 50 to 60 years. Conclusions: Parotid was the most common site whereas Mucoepidermoid carcinoma was the most common malignant tumor of major salivary gland.

Sign in / Sign up

Export Citation Format

Share Document